PMA device
WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology
Boston Scientific Corp · System, Appendage Closure, Left Atrial (NGV, Class III) · First FDA decision Jul 21, 2020, newest Jul 16, 2025Stroke prevention in atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
25
Naming "WATCHMAN FLX"
MAUDE reports
8,032
Brand "WATCHMAN FLX", since 2015
PubMed studies
248
Mentioning "WATCHMAN FLX"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with DeliPMA supplement
P130013-S074 · Decided Jul 16, 2025 · 180 days after receipt · Panel Track
Device type: System, appendage closure, left atrial (NGV) · Cardiology
- WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with Delivery System, WATCHMAN FLX Pro Left Atrial Appendage ClPMA supplement
P130013-S065 · Decided Apr 16, 2024 · 155 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
P130013-S054 · Decided Oct 28, 2022 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: System, appendage closure, left atrial (NGV) · Cardiology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "WATCHMAN FLX", any status and sponsor, newest update first.
- Combined Pulsed-field Ablation (PFA) and Left Atrial Appendage Occlusion Using Watchman Flx or AmuletPivotal-lookingActive, not recruiting
Prince of Wales Hospital, Shatin, Hong KongAcademic, hospital or other
NCT05560204 · 200 participants (planned) · Start Jan 1, 2023 · Primary completion Dec 31, 2027
Device: Combined Pulsed-field Ablation (PFA) + Left Atrial Appendage Occlusion (LAAO) · For: Combined Pulsed-field Ablation (PFA)
Sites: Jordon, Hong Kong; Hong Kong, Hong Kong; Taipa, Macau
- CHAMPION-AF Clinical TrialPivotal-lookingActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT04394546 · 3,000 participants · Start Oct 15, 2020 · Primary completion Dec 2027
Device: WATCHMAN FLX LAAC Device · For: Atrial Fibrillation; Stroke; Bleeding
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 141 sites in all
- SIMPLAAFY Clinical TrialPivotal-lookingActive, not recruiting
Boston Scientific CorporationPublic (BSX)
NCT06521463 · 1,857 participants · Start Oct 1, 2024 · Primary completion Jul 7, 2026
Device: WATCHMAN FLX Pro LAAC Device · For: Atrial Fibrillation; Stroke; Bleeding
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 86 sites in all
22 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "WATCHMAN FLX", and for the whole product code for context.
This brand
8,032 reports: 273 malfunction, 6,838 injury, 921 death
Whole product code NGV
17,771 reports: 1,912 malfunction, 13,990 injury, 1,862 death
Newest reports for this brand
- WATCHMAN FLX? ProInjury
2124215-2026-57534 · Received Oct 29, 2026 · Event dated Oct 21, 2026
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Low Blood Pressure/ Hypotension; Pericardial Effusion
2124215-2026-57556 · Received Oct 29, 2026 · Event dated Sep 29, 2026
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Difficult or Delayed Positioning
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- WATCHMAN FLX?Death
2124215-2026-57562 · Received Oct 29, 2026 · Event dated Jan 14, 2023
Device type: System, Appendage Closure, Left Atrial (NGV)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Cardiac Arrest
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2765-2015 · Started Aug 25, 2015
Reason given: Cross-threading of the hemostasis valve may occur if it is tightened with the dilator in place, possibly preventing subsequent sealing of the valve when desired. This Field Correction reinforces the Directions for Use (DFU) and gives further guidance on correct use of the hemostasis valve to avoid cross-threading and...
Cause as FDA categorized it: Use error · Device type: System, Appendage Closure, Left Atrial (NGV)
Z-2766-2015 · Started Aug 25, 2015
Reason given: Cross-threading of the hemostasis valve may occur if it is tightened with the dilator in place, possibly preventing subsequent sealing of the valve when desired. This Field Correction reinforces the Directions for Use (DFU) and gives further guidance on correct use of the hemostasis valve to avoid cross-threading and...
Cause as FDA categorized it: Use error · Device type: System, Appendage Closure, Left Atrial (NGV)
Published research
The most relevant PubMed records for "WATCHMAN FLX"[tiab]. The summary above synthesizes these.
- Watchman FLX's Sophomore Year Report Card.
Dewland TA · J Am Heart Assoc · 2023Editorial, Comment
- Transcatheter Left Atrial Appendage Closure.
Wong GX, Singh GD · Methodist Debakey Cardiovasc J · 2023
- Over Flexing of the WATCHMAN FLX Muscles in the Real World.
Alkhouli M · Circ Cardiovasc Interv · 2024Editorial, Comment
- Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation.
Kar S, Doshi SK, Alkhouli M, et al. · Am Heart J · 2023Research Support, Non-U.S. Gov't, Clinical Trial Protocol
- Watchman FLX Implantation for Challenging Left Atrial Appendage Anatomy: Case-Based Discussion.
Joury A, Englert JAR, Bernard M, et al. · Curr Probl Cardiol · 2022Review
- Watchman FLX versus Watchman 2.5 for left atrial appendage closure: a propensity score-matched analysis.
Galea R, La Fazia VM, Della Rocca DG, et al. · EuroIntervention · 2025Comparative Study, Multicenter Study
- Intracardiac Echocardiography to Guide Watchman FLX Implantation: The ICE LAA Study.
Nielsen-Kudsk JE, Berti S, Caprioglio F, et al. · JACC Cardiovasc Interv · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- Watchman 2.5TM versus Watchman FLXTM device in atypical left atrial anatomies: old fashion never dies.
Salaun E, Bernier M, Paradis JM, et al. · Acta Cardiol · 2023
- New Left Atrial Appendage Devices: Revelation or Conformal?
Boersma LVA · JACC Clin Electrophysiol · 2022Editorial, Comment
- Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study.
Galea R, Mahmoudi K, Gräni C, et al. · Europace · 2022
- Watchman FLX: Early "Real World" Experience in Search for the Perfect Closure.
Singh GD, Rogers JH, Saw J · JACC Cardiovasc Interv · 2020Editorial, Comment
- Left Atrial Appendage Occlusion With Watchman FLX: Is "Better" Good Enough?
Tzikas A, Samaras A · JACC Cardiovasc Interv · 2025Editorial
Other devices of this type
Also filed under product code NGV.
- Watchman Left Atrial Appendage (Laa) Closure TechnologyBoston Scientific Corp · PMA 2026
- WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery SystemBoston Scientific Corp · PMA 2025
- Amplatzer Amulet Left Atrial Appendage OccluderAbbott Medical · PMA 2025
- Amplatzer Amulet LAA OccluderAbbott Medical · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.